Association of anti-idiotypic antibodies with immune tolerance induction for the treatment of hemophilia A with inhibitors

Haematologica

Volumn 89, Issue 6, 2004, Pages 696-703

  Sakurai, Yoshihiko ^a   Shima, Midori ^a   Tanaka, Ichiro ^a   Fukuda, Kazuyoshi ^a   Yoshida, Koichi ^a   Yoshioka, Akira ^a  

^a NARA MEDICAL UNIVERSITY   (Japan)

Author keywords

Affinity maturation; Antiidiotypic antibody; Hemophilia A; Immune tolerance induction therapy

Indexed keywords

BLOOD CLOTTING FACTOR 7; IDIOTYPIC ANTIBODY; IMMUNOGLOBULIN G; NEUTRALIZING ANTIBODY; PROTEIN G;

ANTIBODY DETECTION; ANTIBODY TITER; ARTICLE; CLINICAL ARTICLE; HEMOPHILIA A; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOPRECIPITATION; PLASMA; TREATMENT OUTCOME;

ANTIBODIES, ANTI-IDIOTYPIC; ANTIBODY FORMATION; AUTOANTIBODIES; FACTOR VIII; HEMOPHILIA A; HUMANS; IMMUNE TOLERANCE;

EID: 3042632206     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Ehrenforth S, Kreuz W, Scharrer I, Linde R, Funk M, Gungor T, et al. Incidence of development of factor VIII and factor IX inhibitors in haemophiliacs. Lancet 1992; 339:594-8.
2. Addiego J, Kasper C, Abildgaard C, Hilgartner M, Lusher J, Glader B, et al. Frequency of inhibitor development in haemophiliacs treated with low-purity factor VIII. Lancet 1993;342:462-4.
3. Lusher JM, Arkin S, Abildgaard CF, Schwartz RS. Recombinant factor VIII for the treatment of previously untreated patients with hemophilia A. Safety, efficacy, and development of inhibitors. Kogenate Previously Untreated Patient Study Group. N Engl J Med 1993;328: 453-9.
4. Bray GL, Gomperts ED, Courter S, Gruppo R, Gordon EM, Manco-Johnson M, et al. A multicenter study of recombinant factor VIII (recombinate): safety, efficacy, and inhibitor risk in previously untreated patients with hemophilia A. The Recombinate Study Group. Blood 1994;83: 2428-35.
5. Rothschild C, Laurian Y, Satre EP, Borel Derlon A, Chambost H, Moreau P, et al. French previously untreated patients with severe hemophilia A after exposure to recombinant factor VIII: incidence of inhibitor and evaluation of immune tolerance. Thromb Haemost 1998;80:779-83.
6. Brackmann HH, Gormsen J. Massive factor-VIII infusion in haemophiliac with factor-VIII inhibitor, high responder. Lancet 1977;2:933.
7. Oldenburg J, Schwaab R, Brackmann HH. Induction of immune tolerance in haemophilia A inhibitor patients by the 'Bonn Protocol': predictive parameter for therapy duration and outcome. Vox Sang 1999; 77 Suppl 1:49-54.
8. Mauser-Bunschoten EP, Nieuwenhuis HK, Roosendaal G, van den Berg HM. Low-dose immune tolerance induction in hemophilia A patients with inhibitors. Blood 1995;86:983-8.
9. Van Leeuwen EF, Mauser-Bunschoten EP, Van Dijken PJ, Kok AJ, Sjamsoedin-Visser EJ, Sixma JJ. Disappearance of factor VIII:C antibodies in patients with haemophilia A upon frequent administration of factor VIII in intermediate or low dose. Br J Haematol 1986;64:291-7.
10. Mauser-Bunschoten EP. Immune tolerance: low dose regimen. In: Rodriguez-Merchan EC, Lee CA, editors. Inhibitors in patients with haemophilia. Oxford, Blackwell; 2002. p. 49-54.
11. nd, Greenwood R, Escobar M, Frelinger JA. Hemophilia factor VIII therapy. Immunological tolerance. A clinical perspective. Haematologica 2000;85 Suppl 10:113-6.
12. Saint-Remy JM. B- and T-cell tolerance: from basic concepts to clinical practice. Haematologica 2000;85 Suppl 10:93-6.
13. Mariani G, Kroner B. Immune tolerance in hemophilia with factor VIII inhibitors: predictors of success. Haematologica 2001;86:1186-93.
14. Pelanda R, Schwers S, Sonoda E, Torres RM, Nemazee D, Rajewsky K. Receptor editing in a transgenic mouse model: site, efficacy, and role of B cell tolerance and antibody diversification. Immunity 1997; 7:765-75.
15. Saint-Remy JM, Jacquemin MG, Gilles JG. Anti-idiotypic antibodies: from regulation to therapy of factor VIII inhibitors. Vox Sang 1999;77 Suppl 1:21-4.
16. Kazatchkine MD, Lacroix-Desmazes S, Moreau A, Kaveri SV. Idiotypic regulation of anti-factor VIII antibodies. Haematologica 2000;85 Suppl 10:97-9.
17. Sultan Y, Kazatchkine MD, Maisonneuve P, Nydegger UE. Anti-idiotypic suppression of autoantibodies to factor VIII (antihaemophilic factor) by high-dose intravenous gammaglobulin. Lancet 1984;2:765-8.
18. Sultan Y, Rossi F, Kazatchkine MD. Recovery from anti-VIII:C (antihemophilic factor) autoimmune disease is dependent on generation of antiidiotypes against anti-VIII:C autoantibodies. Proc Natl Acad Sci USA 1987;84:828-31.
19. Rossi F, Sultan Y, Kazatchkine MD. Anti-idiotypes against autoantibodies and alloantibodies to VIII:C (anti-haemophilic factor) are present in therapeutic poly-specific normal immunoglobulins. Clin Exp Immunol 1988;74:311-6.
20. Gilles JG, Arnout J, Vermylen J, Saint-Remy JM. Anti-factor VIII antibodies of hemophiliac patients are frequently directed towards nonfunctional determinants and do not exhibit isotypic restriction. Blood 1993;82:2452-61.
21. Sultan Y, Kazatchkine MD, Nydegger U, Rossi F, Dietrich G, Algiman M. Intravenous immunoglobulin in the treatment of spontaneously acquired factor VIII:C inhibitors. Am J Med 1991;91:35S-39S.
22. Gilles JG, Desqueper B, Lenk H, Vermylen J, Saint-Remy JM. Neutralizing antiidiotypic antibodies to factor VIII inhibitors after desensitization in patients with hemophilia A. J Clin Invest 1996;97: 1382-8.
23. Kasper CK, Aledort L, Aronson D, Counts R, Edson JR, van Eys J, et al. A more uniform measurement of factor VIII inhibitors. Thromb Diathes Haemorh 1975; 34:869-72.
24. Hoyer LW, Scandella D. Factor VIII inhibitors: structure and function in autoantibody and hemophilia A patients. Semin Hematol 1994;31 Suppl 4:1-5.
25. Dietrich G, Algiman M, Sultan Y, Nydegger UE, Kazatchkine MD. Origin of antiidiotypic activity against anti-factor VIII autoantibodies in pools of normal human immunoglobulin G (IVIg). Blood 1992;79: 2946-51.
26. Gilles JG, Saint-Remy JM. Healthy subjects produce both anti-factor VIII and specific anti-idiotypic antibodies. J Clin Invest 1994;94:1496-505.
27. Algiman M, Dietrich G, Nydegger UE, Boieldieu D, Sultan Y, Kazatchkine MD. Natural antibodies to factor VIII (anti-hemophilic factor) in healthy individuals. Proc Natl Acad Sci USA 1992;89:3795-9.
28. Scandella D, Mondorf W, Klinge J. The natural history of the immune response to exogenous factor VIII in severe haemophilia A. Haemophilia 1998;4: 546-51.
29. Scandella D. Human anti-factor VIII antibodies: epitope localization and inhibitory function. Vox Sang 1996; 70 Suppl 1: 9-14.
30. Dazzi F, Tison T, Vianello F, Radossi P, Zerbinati P, Carraro P, et al. High incidence of anti-FVIII antibodies against non-coagulant epitopes in haemophilia A patients: a possible role for the half-life of transfused FVIII. Br J Haematol 1996; 93:688-93.
31. Lange H, Solterbeck M, Berek C, Lemke H. Correlation between immune maturation and idiotypic network recognition. Eur J Immunol 1996;26:2234-42.